BioNexus Gene Lab (BGLC) Return on Invested Capital (2019 - 2022)

BioNexus Gene Lab has reported Return on Invested Capital for 4 years, with the latest figure at 0.03% in Q4 2022.

• Quarterly Return on Invested Capital fell 7.0% year-over-year to 0.03% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 0.03% (down 7.0% YoY) and the FY2021 annual result came in at 0.17%, down 1.0% from the prior year.
• Return on Invested Capital fell to 0.03% in Q4 2022 per BGLC's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.05% in Q3 2020 and troughed at 0.03% in Q4 2022.
• A 4-year average of 0.02% and a median of 0.02% in 2022 frame the typical range for Return on Invested Capital.
• The sharpest annual moves came in 2020 and 2022: Return on Invested Capital increased 6 bps in 2020, then fell 7 bps in 2022.
• Over 4 years, Return on Invested Capital stood at 0.01% in 2019, then soared by 431 bps to 0.05% in 2020, then decreased by 7 bps to 0.04% in 2021, then sank by 158 bps to 0.03% in 2022.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.03%, 0.01%, and 0.02% for Q4 2022, Q3 2022, and Q2 2022 respectively.